Rikke Hedegaard Dahlrot

List of Publications by Year in Descending Order

41 papers	1,262 citations	20 h-index	35 g-index
43 ext. papers	1,602 ext. citations	3.1 avg, IF	4.67 L-index

#	Paper	IF	Citations
41	Metastatic atypical renal tumour with metanephric characteristics treated with Sunitinib. *Urology Case Reports*, **2022**, 40, 101880	0.5	0
40	Treatment plan comparison of proton vs photon radiotherapy for lower-grade gliomas. *Physics and Imaging in Radiation Oncology*, **2021**, 20, 98-104	3.1	0
39	A national study on the inter-observer variability in the delineation of organs at risk in the brain. *Acta Oncologica*, **2021**, 60, 1548-1554	3.2	1
38	Targeted next-generation sequencing of adult gliomas for retrospective prognostic evaluation and up-front diagnostics. *Neuropathology and Applied Neurobiology*, **2021**, 47, 108-126	5.2	3
37	Quality of life in patients with cancer during the COVID-19 pandemic - a Danish cross-sectional study (COPICADS). *Acta Oncologica*, **2021**, 60, 4-12	3.2	15
36	Evolution of the gross tumour volume extent during radiotherapy for glioblastomas. *Radiotherapy and Oncology*, **2021**, 160, 40-46	5.3	3
35	P14.69 Trends in postoperative chemoradiotherapy for Glioblastoma patients: a Danish cohort study. *Neuro-Oncology*, **2021**, 23, ii51-ii51	1	
34	Prognostic role of Ki-67 in glioblastomas excluding contribution from non-neoplastic cells. *Scientific Reports*, **2021**, 11, 17918	4.9	1
33	Study protocol for OptimalTTF-2: enhancing Tumor Treating Fields with skull remodeling surgery for first recurrence glioblastoma: a phase 2, multi-center, randomized, prospective, interventional trial. *BMC Cancer*, **2021**, 21, 1010	4.8	2
32	Posttreatment Effect of MGMT Methylation Level on Glioblastoma Survival. *Journal of Neuropathology and Experimental Neurology*, **2019**, 78, 633-640	3.1	8
31	GENE-33. INTEGRATED GLIOMA DIAGNOSTICS USING TARGETED NEXT-GENERATION SEQUENCING. *Neuro-Oncology*, **2019**, 21, vi104-vi104	1	78
30	Prognostic value of O-6-methylguanine-DNA methyltransferase (MGMT) protein expression in glioblastoma excluding nontumour cells from the analysis. *Neuropathology and Applied Neurobiology*, **2018**, 44, 172-184	5.2	20
29	Evaluation of the proliferation marker Ki-67 in gliomas: Interobserver variability and digital quantification. *Diagnostic Pathology*, **2018**, 13, 38	3	14
28	Plan quality for high-risk prostate cancer treated with high field magnetic resonance imaging guided radiotherapy. *Physics and Imaging in Radiation Oncology*, **2018**, 7, 1-8	3.1	11
27	Tumour-associated microglia/macrophages predict poor prognosis in high-grade gliomas and correlate with an aggressive tumour subtype. *Neuropathology and Applied Neurobiology*, **2018**, 44, 185-206	5.2	105
26	P04.25 Expression and prognostic value of the transcription factors EGR1 and EGR3 in gliomas. *Neuro-Oncology*, **2018**, 20, iii284-iii284	1	78
25	P01.114 Expression and prognostic value of the immune checkpoint molecule galectin-9 in glioblastomas. *Neuro-Oncology*, **2018**, 20, iii257-iii258	1	78

24	P01.083 Expression and prognostic value of the immune checkpoint molecule galectin-9 in glioblastomas. *Neuro-Oncology*, **2018**, 20, iii249-iii249	1	78
23	P04.41 Expression and prognostic value of the transcription factors EGR1 and EGR3 in gliomas. *Neuro-Oncology*, **2018**, 20, iii288-iii288	1	78
22	Aberrant neuronal differentiation is common in glioma but is associated neither with epileptic seizures nor with better survival. *Scientific Reports*, **2018**, 8, 14965	4.9	3
21	Expression and prognostic value of JAM-A in gliomas. *Journal of Neuro-Oncology*, **2017**, 135, 107-117	4.8	8
20	APNG as a prognostic marker in patients with glioblastoma. *PLoS ONE*, **2017**, 12, e0178693	3.7	8
19	Transferrin receptor-1 and ferritin heavy and light chains in astrocytic brain tumors: Expression and prognostic value. *PLoS ONE*, **2017**, 12, e0182954	3.7	36
18	Trends in tumors in the central nervous system in elderly in Denmark, 2008-2012. *Acta Oncologica*, **2016**, 55 Suppl 1, 91-7	3.2	9
17	Development and validation of a prognostic model for recurrent glioblastoma patients treated with bevacizumab and irinotecan. *Acta Oncologica*, **2016**, 55, 418-22	3.2	10
16	Expression and prognostic value of the WEE1 kinase in gliomas. *Journal of Neuro-Oncology*, **2016**, 127, 381-9	4.8	39
15	Glioma Cells in the Tumor Periphery Have a Stem Cell Phenotype. *PLoS ONE*, **2016**, 11, e0155106	3.7	21
14	High levels of c-Met is associated with poor prognosis in glioblastoma. *Journal of Neuro-Oncology*, **2015**, 122, 517-27	4.8	47
13	STEM-13EXPRESSION OF STEM CELL, PROLIFERATION AND CHEMORESISTANCE MARKERS IN GLIOMA CELLS IN THE TUMOR PERIPHERY. *Neuro-Oncology*, **2015**, 17, v210.5-v211	1	78
12	TMIC-18TUMOR-ASSOCIATED MICROGLIA/MACROPHAGES ARE ASSOCIATED WITH POOR PROGNOSIS IN HIGH-GRADE GLIOMAS AND CONTRIBUTE TO THE GLIOBLASTOMA STEM CELL-LIKE NICHES. *Neuro-Oncology*, **2015**, 17, v218.6-v218	1	78
11	Determining viability of using APNG status as a prognostic marker in patients with glioblastoma multiforme.. *Journal of Clinical Oncology*, **2015**, 33, 2028-2028	2.2	
10	High-throughput flow cytometry screening reveals a role for junctional adhesion molecule a as a cancer stem cell maintenance factor. *Cell Reports*, **2014**, 6, 117-29	10.6	61
9	Novel approaches for quantifying protein biomarkers in gliomas: benefits and pitfalls. *CNS Oncology*, **2014**, 3, 287-98	4	8
8	Clinical value of CD133 and nestin in patients with glioma: a population-based study. *International Journal of Clinical and Experimental Pathology*, **2014**, 7, 3739-51	1.4	39
7	The prognostic value of clinical factors and cancer stem cell-related markers in gliomas. *Danish Medical Journal*, **2014**, 61, B4944	3.8	14

6	A population-based study of low-grade gliomas and mutated isocitrate dehydrogenase 1 (IDH1). *Journal of Neuro-Oncology*, **2013**, 114, 309-17	4.8	29
5	MiR-21 expression in the tumor cell compartment holds unfavorable prognostic value in gliomas. *Journal of Neuro-Oncology*, **2013**, 111, 71-81	4.8	80
4	Prognostic value of Musashi-1 in gliomas. *Journal of Neuro-Oncology*, **2013**, 115, 453-61	4.8	36
3	A population-based study of high-grade gliomas and mutated isocitrate dehydrogenase 1. *International Journal of Clinical and Experimental Pathology*, **2013**, 6, 31-40	1.4	28
2	What is the clinical value of cancer stem cell markers in gliomas?. *International Journal of Clinical and Experimental Pathology*, **2013**, 6, 334-48	1.4	57
1	C-met, a new prognostic biomarker in glioblastoma multiforme.. *Journal of Clinical Oncology*, **2013**, 31, 2088-2088	2.2	